DTU
DTU

Professor Amanda Adler

Picture of AmandaAdler

Position:Director

Telephone:01865 857240

Email:amanda.adler@dtu.ox.ac.uk

Amanda Adler trained in economics, medicine, and epidemiology in the US, and pharmacovigilance in the UK. In 2019, she returned to Oxford University to lead the Diabetes Trial Unit, DTU. The DTU runs studies to address interventions related to diabetes and endocrinology to improve health and collaborates closely with the Health Economic Research Centre.

She chaired a Technology Appraisal Committee at the National Institute for Health and Care Excellence (NICE) for 12 years evaluating over one hundred drugs and devices across disease areas. With NICE, she chaired the committee addressing new models to evaluate and purchase antimicrobials, chaired the Clinical Guidelines for Newer Agents for Type 2 Diabetes and chaired the Quality Standard for Diabetes. She received an award for Distinguished Contribution to NICE at the Parliamentary ceremony celebrating NICE’s 20th anniversary.

She chairs the World Health Organisation Technical Advisory Group for Diabetes. She sees patients who have diabetes in the NHS. She is a Commissioner on the Commission on Human Medicines (CHM) and chairs the CHM’s Expert Advisory Group Cardiovascular, Diabetes, Renal, Respiratory and Allergy, and previously chaired the Medicines and Health Products Regulatory Agency’s Expert Group on the Safety of Insulin. She sits on the National Diabetes Audit Partnership Board and an NIHR funding committee. She supports projects that set priorities under universal health coverage having worked with the UK government, NICE, International Decision Support Initiative, the World Bank, and Organisation for Economic Co-operation and Development (OECD). She is a Fellow of the Royal Statistical Society.

Latest publications

Manuscript
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - Authors' reply
Milad Nazarzadeh et al.
Lancet Diabetes Endocrinol. 2022;10:841-842

Manuscript
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis
Milad Nazarzadeh et al.
Lancet Diabetes Endocrinol. 2022;10:645-54

Manuscript
NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma
Amanda I Adler et al.
Lancet Resp Med 2022;1-2

Manuscript
Nintedanib for treating progressive fibrosing interstitial lung diseases
Amanda I Adler et al.
The Lancet 2021;1-2

Manuscript
Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study
Patrick Bidulka et al.
BMJ Open 2021;11:1-9

Manuscript
Increased Risk of Incident Heart Failure and Death is Associated with Insulin Resistance in People with Newly- Diagnosed Type 2 Diabetes: UKPDS 89
Malgorzata Wamil et al.
Diabetes Care 2021;44:1-8